Temporal association of sNfL and gad-enhancing lesions in multiple sclerosis.
Adult
Biological Assay
Biomarkers
/ blood
Brain
/ diagnostic imaging
Female
Gadolinium
Humans
Image Enhancement
Longitudinal Studies
Magnetic Resonance Imaging
Male
Multiple Sclerosis
/ blood
Neurofilament Proteins
/ blood
Optic Nerve
/ diagnostic imaging
Recurrence
Severity of Illness Index
Spinal Cord
/ diagnostic imaging
Time Factors
Journal
Annals of clinical and translational neurology
ISSN: 2328-9503
Titre abrégé: Ann Clin Transl Neurol
Pays: United States
ID NLM: 101623278
Informations de publication
Date de publication:
06 2020
06 2020
Historique:
received:
08
10
2019
revised:
26
02
2020
accepted:
25
04
2020
pubmed:
27
5
2020
medline:
20
4
2021
entrez:
27
5
2020
Statut:
ppublish
Résumé
Multiple sclerosis (MS) is an autoimmune demyelinating disorder, which is characterized by relapses and remissions. Serum neurofilament light chain (sNfL) is an emerging biomarker of disease activity but its clinical use is still limited. In this study, we aim to characterize the temporal association between sNfL and new clinical relapses and new gadolinium-enhancing (Gd+) lesions. Annual sNfL levels were measured with a single-molecule array (SIMOA) assay in 94 patients with MS enrolled in the Comprehensive Longitudinal Investigation of Multiple Sclerosis at the Brigham and Women's Hospital (CLIMB) study. We used a multivariable linear mixed-effects model to test the temporal association of sNfL with clinical relapses and/or new Gd+ lesions. We adjusted this model for age, disease duration, sex, and disease-modifying therapies (DMTs) use. In the 3 months after a Gd+ lesion, we observed an average 35% elevation in sNfL (P < 0.0001) compared to remission samples. We also observed an average 32.3% elevation in sNfL at the time of or prior to a Gd+ lesion (P = 0.002) compared to remission. We observed a significant elevation in sNfL after a clinical relapse only when associated with a Gd+ lesion. Our findings support sNfL as a marker of clinical relapses and Gd+ lesions. sNfL peaks in a 3-month window around Gd+ lesions. sNfL shows promise as a biomarker of neurological inflammation and possibly of simultaneous Gd+ lesions during a clinical relapse.
Identifiants
pubmed: 32452160
doi: 10.1002/acn3.51060
pmc: PMC7318095
doi:
Substances chimiques
Biomarkers
0
Neurofilament Proteins
0
neurofilament protein L
0
Gadolinium
AU0V1LM3JT
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
945-955Subventions
Organisme : U.S. Department of Defense
ID : W81XWH-18-1-0648
Pays : International
Informations de copyright
© 2020 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.
Références
Brain. 2006 Mar;129(Pt 3):606-16
pubmed: 16415308
Neuron. 2016 Jul 6;91(1):1-3
pubmed: 27387643
Ann Clin Transl Neurol. 2018 Oct 16;5(12):1478-1491
pubmed: 30564615
Neurology. 2015 Aug 25;85(8):722-9
pubmed: 26208962
J Neurol Neurosurg Psychiatry. 1998 Mar;64(3):402-4
pubmed: 9527161
Ann Neurol. 2011 Feb;69(2):292-302
pubmed: 21387374
Neurol Neuroimmunol Neuroinflamm. 2017 Nov 28;5(1):e422
pubmed: 29209636
Neurology. 2019 Mar 5;92(10):e1007-e1015
pubmed: 30737333
Mult Scler. 2016 Oct;22(12):1550-1559
pubmed: 26754800
Neurotherapeutics. 2007 Jul;4(3):485-98
pubmed: 17599713
EBioMedicine. 2015 Nov 22;3:135-140
pubmed: 26870824
Ann Neurol. 2017 Jun;81(6):857-870
pubmed: 28512753
Mult Scler. 2019 Apr;25(5):678-686
pubmed: 29542376
Neurology. 2017 Nov 21;89(21):2167-2175
pubmed: 29070659
Neurology. 2003 Dec 23;61(12):1720-5
pubmed: 14694036
Eur J Neurol. 2017 Jan;24(1):112-121
pubmed: 27699930
Clin Chem Lab Med. 2016 Oct 1;54(10):1655-61
pubmed: 27071153
Neurology. 2015 Apr 21;84(16):1639-43
pubmed: 25809304
Innov Clin Neurosci. 2017 Apr 01;14(3-4):38-40
pubmed: 28584696
Brain. 2018 Aug 1;141(8):2382-2391
pubmed: 29860296
Amyotroph Lateral Scler Frontotemporal Degener. 2017 Feb;18(1-2):112-119
pubmed: 27819158
Ann N Y Acad Sci. 1965 Mar 31;122:552-68
pubmed: 14313512
Nat Rev Neurol. 2018 Oct;14(10):577-589
pubmed: 30171200
J Neurol. 2008 Feb;255(2):280-7
pubmed: 18204919
J Neurochem. 1996 Nov;67(5):2013-8
pubmed: 8863508
J Neurosci. 2012 May 2;32(18):6209-19
pubmed: 22553027
Neurology. 2017 May 9;88(19):1788-1794
pubmed: 28404801
Mult Scler. 2018 Jul;24(8):1046-1054
pubmed: 28627962
Neurology. 2003 Dec 9;61(11):1528-32
pubmed: 14663037
Neurology. 2017 Feb 28;88(9):826-831
pubmed: 28148632
J Neuroinflammation. 2018 Jul 18;15(1):209
pubmed: 30021640
Ann Clin Transl Neurol. 2016 Jul 01;3(8):623-36
pubmed: 27606344
Mult Scler. 2018 Sep;24(10):1270-1271
pubmed: 30066596
Neurology. 2017 Nov 28;89(22):2230-2237
pubmed: 29079686
Autoimmun Rev. 2006 Oct;5(8):532-6
pubmed: 17027888
JAMA Neurol. 2017 May 1;74(5):557-566
pubmed: 28346578